Exclusive Life Science Feature
The Micro-Innovators
Small Enterprises Make Outsized
Contributions With Novel Drugs.
By Wayne Koberstein, executive editor
S
o simple in concept — interview three CEOs of companies
developing novel drugs — so challenging in execution.
Who would have guessed there is such a strong correlation
between novel-drug development and small-company volatility?
Since my investigation began, one company replaced its CEO and
changed its name, another's stock rose and fell repeatedly on news
of a competing product, and a third one joined late in place of
another that dropped out. All of those events are among the most
common disruptions in business and communications for the
micro-enterprises focused on unique paths of medical innovation.
Thus, I stumbled upon a key insight into the lives of this industry's
micro-innovators — it's never easy.
26
LifeScienceLeader.com
December 2013